A Phase 1b Randomized, Observer-Blind, Placebo-Controlled Study to Evaluate the Safety and Immunogenicity of a Prime-Boost Regimen of Three Dose Levels of PHV02, a Nipah Virus Vaccine Candidate (rVSV-ΔG-EBOV GP-NiVG) in Healthy Adults

The goal of this clinical trial is to test the safety and immunogenicity of PHV02 live, attenuated recombinant vesicular stomatitis virus vaccine expressing the Nipah Virus glycoprotein in healthy adult subjects. The main questions it aims to answer are:
* which doses of PHV02 are safe to administer to and well-tolerated by healthy adult subjects as a 2 dose regimen given 1 month apart?
* what is the immunologic response (Nipah-specific IgG ELISA antibody and neutralizing antibodies) to each dose level after a 2-dose regimen given 1 month apart? Participants will receive 2 intramuscular injections of PHV02 (2x105, 2x106, and 2x107 plaque-forming units [pfu]) or placebo on Day 1 and Day 29 and will be followed for 197 days.

Start Date26 Jan 2024

Sponsor / Collaborator

Public Health Vaccines LLC

[+1]

NCT05178901 / CompletedPhase 1

A Phase 1 Randomized, Single Center, Double-Blind, Placebo-Controlled, Dose-Response and Open-Label or Single Blind Booster Study to Evaluate the Safety and Immunogenicity of RVSV-Nipah Virus Vaccine Candidate PHV02 in Healthy Adult Subjects

A Phase 1 Study to Evaluate the Safety and Immunogenicity of rVSV-Nipah Virus Vaccine Candidate PHV02 in Healthy Adult Subjects

Start Date10 Jan 2022

Sponsor / Collaborator

Public Health Vaccines LLC

[+1]

100 Clinical Results associated with rVSV Nipah vaccine(Public Health Vaccines)

100 Translational Medicine associated with rVSV Nipah vaccine(Public Health Vaccines)

100 Patents (Medical) associated with rVSV Nipah vaccine(Public Health Vaccines)

Literatures (Medical) associated with rVSV Nipah vaccine(Public Health Vaccines)

01 Oct 2024·Journal of Infection

Replication, safety and immunogenicity of the vectored Ebola vaccine rVSV-ΔG-ZEBOV-GP in a sub-Saharan African paediatric population: A randomised controlled, open-label trial in children aged 1-12 years living in Lambaréné, Gabon

Article

Author: Kavishna, Ranmali ; Agnandji, Selidji T ; Velavan, Thirumalaisamy P ; Harandi, Ali M ; Musangomunei, Fungai P ; Olubiyi, Bisola F ; Rothenberger, Sylvia ; Nakaya, Helder I ; Siegrist, Claire-Anne ; Kabwende, Anita L ; Medaglini, Donata ; Kokou, Kossiwa ; Mahmoudou, Saidou ; Engler, Olivier ; Alabi, Ayodele ; Nakka, Sravya S ; Kremsner, Peter G ; Bie-Ondo, Juste C

BACKGROUNDUnlike adults, children experienced stronger and longer vector replication in plasma and shedding in saliva following rVSVΔG-ZEBOV-GP vaccination. The resulting risks of immunosuppression or immune hyperactivation leading to increased Adverse Events (AEs) and altered antibody responses are concerns that have been addressed in the present manuscript.METHODSChildren aged 1-12 years living in Gabon received either rVSVΔG-ZEBOV-GP (ERVEBO®) vaccine or the varicella-zoster virus (VZV) vaccine (VZV). The concentration of rVSVΔG vector in blood and saliva, the occurrence of AEs up to day 28; the anti-rVSVΔG-ZEBOV-GP and anti-VZV IgG antibody titres, neutralising and avidity functions of anti-rVSVΔG-ZEBOV-GP by day 365; were assessed in serum. (PACTR202005733552021) FINDINGS: In the rVSVΔG-ZEBOV-GP group, 70% and 7% of children had > 0 copies/ml of rVSVΔG respectively in plasma by day 3 and in saliva by day 14 after vaccination, with no detection on day 28. Significantly higher but transient AEs occurred in the rVSVΔG-ZEBOV-GP group. Both vaccines induced seroconversion on day 28 and sustainable IgG antibody titres by day 365. Avidity and neutralisation functions of the anti-rVSVΔG-ZEBOV-GP antibodies peaked at day 28 and were maintained by day 365.INTERPRETATIONThe replication and shedding do not affect the favourable risk-benefit balance of the rVSVΔG-ZEBOV-GP in children.FUNDINGThis trial is funded by the Innovative Medicines Initiative 2 (IMI 2) Joint Undertaking (grant number: 116068). The Biomedicine and Social Sciences research team of CERMEL is funded by the European and Developing Countries Clinical Trials Partnership (EDCTP-TMA-SF-1946-VARSAF).

01 May 2024·Tropical Medicine & International Health

Current progress towards prevention of Nipah and Hendra disease in humans: A scoping review of vaccine and monoclonal antibody candidates being evaluated in clinical trials

Review

Author: Nafade, Vaidehi ; Yao, Jacqueline ; Basta, Nicole E ; Rodrigue, Valerie ; Gravagna, Katie

AbstractObjectivesNipah and Hendra are deadly zoonotic diseases with pandemic potential. To date, no human vaccine or monoclonal antibody (mAb) has been licensed to prevent disease caused by these pathogens. The aim of this scoping review was to identify and describe all Phase I, II, and III clinical trials of vaccine candidates or mAbs candidates designed to prevent Nipah and Hendra in humans and to compare the characteristics of the vaccine candidates to characteristics outlined in the Target Product Profile drafted by the World Health Organisation as part of the WHO Research & Development Blueprint for Action to Prevent Epidemics.MethodsWe searched 23 clinical trial registries, the Cochrane Central Register of Clinical Trials, and grey literature up to June 2023 to identify vaccine and mAb candidates being evaluated in registered clinical trials. Vaccine candidate and trial characteristics were double‐extracted for evaluation and the vaccine candidate characteristics were compared with the preferred and critical criteria of the World Health Organisation's Target Product Profile for Nipah virus vaccine.ResultsThree vaccine candidates (Hendra Virus Soluble Glycoprotein Vaccine [HeV‐sG‐V], PHV02, and mRNA‐1215) and one mAb (m102.4) had a registered human clinical trial by June 2023. All trials were phase 1, dose‐ranging trials taking place in the United States of America or Australia and enrolling healthy adults. Although all vaccine candidates meet the dose regimen and route of administration criteria of the Target Product Profile, other criteria such as measures of efficacy and reactogenicity will need to be evaluated in the future as evidence becomes available.ConclusionMultiple vaccine candidates and one mAb candidate have reached the stage of human clinical trials and are reviewed here. Monitoring progress during evaluation of these candidates and candidates entering clinical trials in the future can help highlight many of the challenges that remain.

10 Apr 2024·Clinical Infectious Diseases

Immunogenicity and Vaccine Shedding After 1 or 2 Doses of rVSVΔG-ZEBOV-GP Ebola Vaccine (ERVEBO®): Results From a Phase 2, Randomized, Placebo-controlled Trial in Children and Adults

Article

Author: Kohn, Brian ; Jato, Yvonne ; Masson, Laure ; Roy, Céline ; Michavila, Pauline ; Hendriks, Jenny ; Levy-Marchal, Claire ; Brady, Tyler ; Grandits, Greg ; Barrington, Kesha ; Kojan, Richard ; Aguirre-MacKenzie, Michelle ; Chung, Florence ; Diallo, Mamadou Saliou ; Fayiah, John ; Tchos, Karine Fouth ; Kagan, Jonathan ; Fleck, Suzanne ; D'Ortenzio, Eric ; Boison, Patricia ; Chea, Michael ; Beavogui, Abdoul Habib ; McLean, Chelsea ; Peiffer-Smadja, Nathan ; Diakite, Mahamadou ; Bosompem, Samuel ; Camara, Aboubacar Keira ; Cline-Cole, Elfrida ; Neaton, James ; Subramaniam, Guna ; Sow, Ydrissa ; Coller, Beth-Ann G ; Wallet, Cedrick ; Fofana, Vemy ; Lysander, Julia ; Kollie, David ; Cisse, Papa Ndiaga ; Patel, Sushma ; Diarra, Ayouba ; Coller, Beth-Ann ; Cai, Yingyun ; Dighero-Kemp, Bonnie ; Cash, Jennifer ; Grue, Louis ; Schwimmer, Christine ; Richert, Laura ; Coulibaly, Mariam ; Lambeth, Courtney ; Kirchoff, Matthew ; Gichini, Harrison ; Bagayoko, Aminata ; Liang, Janie ; Matard, Charly ; Blie, Julie ; Surugue, Léa ; VanRheenen, Susan ; Diallo, Alpha ; Kowuor, Dickens ; Ale, Boni Maxime ; Cooper, Joseph Boye ; Pettitt, James ; Hyatt, Donna ; Lee, Andrew W ; Sahr, Philip ; Willems, Wouter ; Siddiqui, Sophia ; Deen, Gibrilla Fadlu ; Fallah, Mosoka ; Serry-Bangura, Alimamy ; Connor, Laurie ; Sow, Amadou ; Watson-Jones, Deborah ; Soutthiphong, Anne-Aygline ; Lawal, Bolarinde ; Haidara, Fadima ; Fakoli, Lawrence ; Samake, Sibiry ; Hoover, Marie ; Hamzé, Benjamin ; Marchand, Jonathan ; Bolay, Fatorma ; Lacarra, Boris ; Nelson, Micki ; Bozman, Courtney ; Keita, Sakoba ; Etienne, Cécile ; Lowe, Brett ; Clifford Lane, H ; Yarmie, Quiawiah ; Yaradouno, Marcel ; Owens, Abigail ; Colin, Céline ; Hensley, Lisa E ; Shobayo, Bode ; Schvartz, Maxime ; Aboulhab, Jamila ; Mercier, Noémie ; Dekeyster, Eline ; Orsega, Susan ; Newell, Kevin ; Rivière, Priscille ; Alimamy-Bangura, Serry ; Ndamenyaa, Rita Lukoo ; Thompson, Greg ; Chai, Siew Pin ; Augier, Augustin ; Whitworth, Hilary ; Secka, Fatou ; Simpson, Shelly ; Lhomme, Edouard ; Baseler, Beth ; Lambert, Laurie ; DuChêne, Alain ; Simon, Jakub K ; Lacabaratz, Christine ; Keita, Cheick Mohamed ; Doumbia, Seydou ; Nair, Sunita ; McCullough, John ; Yazdanpanah, Yazdan ; Kiawu, Hassan ; Liu, Ken ; Touré, Abdoulaye ; Davis, Bionca ; Kolié, Cece Francis ; Gross, Robin ; Chêne, Geneviève ; Balde, Abby ; Joe, Madison ; Neboua, Désiré ; Bockstal, Viki ; Billouin-Frazier, Shere ; Grund, Birgit ; Tierney, John ; Holley, Horace Preston ; Balssa, Joséphine ; Wilson, Barthalomew ; Kwast, Liane ; Kpayieli-Freeman, Catherine ; Wiedemann, Aurelie ; Pierson, Jerome ; Gallagher, Katherine ; Tyee, Tijili ; Akpa, Esther ; Zhou, Huanying ; Swales, Nathalie ; Douoguih, Macaya ; Shelley, Denise ; Faye, Sylvain ; Lee, Andrew Wen-Tseng ; Cauwelaert, Natasha Dubois ; Thiebaut, Rodolphe ; Phillips, Robert ; Vogel, Susan ; Wolf, Jayanthi ; Kopka, Stacy ; Browne, Sarah ; Conde, Djélikan Siaka ; Lemarcis, Frederic ; Kocher, Gregory ; Mulbah, James ; Nguyen, Vinh-kim ; Djenabou, Barry ; Termote, Monique ; Piziali, Micheal ; Leyssen, Maarten ; Vatrinet, Renaud ; Eckes, Risa ; Linga, Mameni ; Kaba, Aboubacar Sidiki ; Gozalbes, Julia Garcia ; Ciancia, Séverine ; Mahamadou, Ibrah ; Sanogo, Ibrahim ; Koroma, Bockarie ; Kamara, Michael ; Piot, Peter ; Miranda, Alejandra ; Zeggani, Zara ; Hensley, Patricia ; Beavogui, Abdoul H ; Chung, Lucy ; Lees, Shelley ; Yamadjako, Delphine ; Irvine, Skip ; Lévy, Yves ; Diouf, Waly ; Albert, Sara ; Delmas, Christelle ; Weaver, Wade ; Onorato, Matthew T ; Osborne, Cynthia ; Awuondo, Ken ; Cahill, Kelly ; Espérou, Hélène ; Traore, Awa ; Gaignet, Marylène ; Towalid, Elvis ; Tangara, Cheick ; Diop, Samba ; Keita, Seykou ; Doumbia, Moussa Moise ; Camara, Alseny Modet ; Duvenhage, Michael ; Billioux, Jeanne ; Delfraissy, Jean-François ; Keshinro, Babajide ; Enria, Luisa ; Massaquoi, Moses B F ; Pong, Stéphany ; Ishola, David ; Crew, Page ; Badio, Moses ; Smout, Elizabeth ; Boly, Aliou ; Morgan, Amy ; Ortega-Perez, Inmaculada ; Sayadi, Sani ; Katoudi, Judith ; Warren, Travis ; de Saint Fare, Eric Barte ; Wurie, Alie ; Kolié, Jacques Seraphin ; Vallée, David ; Bererd, Marion ; Sow, Samba O ; Dixit, Saurabh ; Beyslow, Teedoh ; Gray, Maima ; Hilton, Trudi ; Miller, Tracey ; Tegli, Jemee ; Russell, Amy Falk ; Lee, Shona ; Andong, Pierre ; Traina, Stacey ; Vincent, Corine ; Hughes, Melissa ; Campagne, Antoine ; Manno, Daniela ; Ilo, Dicko ; Peart, Danielle ; Hancox, Emma ; Hensley, Lisa ; Onwuchekwa, Uma ; Lefevre, Annabelle ; Muamba, Dally ; Oulaï, Davy ; Quigley, Sinead ; Anoma, Stephane ; Sawadogo, Serge ; Teahton, Julius ; Quach, Alexandre ; Mambiah, Marvington ; Atri, Negin ; Elliott, Elizabeth ; Yu, Shuiqing ; Diarra, Samba ; Bauduin, Claire ; Cone, Katherine ; Welebob, Carolee ; Tapia, Milagritos D ; Wentworth, Deborah ; Coulibaly, Fatoumata ; Wesseh, Cecelia ; Kennedy, Stephen B ; Chambelin, Francois ; Couffin-Cardiergues, Sandrine ; Franklin, Kokulo ; Gupta, Swati ; Higgs, Elisabeth ; Diawara, Oualy ; Akoo, Pauline ; Binachon, Blandine ; Samai, Mohamed ; Simon, Jakub ; Onorato, Matthew ; Damerval, Thierry ; Smolskis, Mary ; Slater, Karen ; Njoh, Wissedi ; Millimouno, Niouma Pascal ; Fusco, Daniela ; Sandrus, Jen ; Snowden, Emily ; Kieh, Mark ; Stirratt, Michael ; Tamba, Sienneh ; Marron, Lindsay ; Njie, Yusupha ; Greenwood, Brian ; Dabitao, Djeneba ; Eyler, Allison ; Postnikova, Elena ; Tindanbil, Daniel ; Borg, Anne-Gaëlle ; Stoop, Jeroen ; Mazur, Steven ; Doepel, Laurie ; Sharma, Heema ; Bauder, Ali ; Leigh, Bailah ; Dabakuyo-Yonli, Sandrine ; Camara, Aissata Abdoulaye ; Bawo, Luke ; Kante, Myriam ; Robinson, Cynthia ; Proffitt, Calvin ; Campion, Cécilia ; Tang, Chan ; Otieno, Tuda ; Deutsch, Jonathan ; Lancrey-javal, Solange ; Mohamed, Soumaya ; Grobler, Nico ; Cagniard, Barbara ; Gaddah, Auguste ; Langba, Shadrach ; Koivogui, Lamine ; Sivahera, Billy Muyisa ; Sarro, Yeya Sadio ; Randunu, Nadeeka ; Andrews, Benetta C ; Guindo, Oumar ; Akpata, Robert ; Mooney, Tom ; Hébert, Jean-Christophe ; Johnson, Melvin ; Dozier, Nelson ; Connor, Nicholas ; Belson, Michael ; Bangura, Lamin Molecule ; Dubey, Sheri ; Chouinard, Michelle ; Kodio, Mamoudou

AbstractBackgroundThe rVSVΔG-ZEBOV-GP vaccine (ERVEBO®) is a single-dose, live-attenuated, recombinant vesicular stomatitis virus vaccine indicated for the prevention of Ebola virus disease (EVD) caused by Zaire ebolavirus in individuals 12 months of age and older.MethodsThe Partnership for Research on Ebola VACcination (PREVAC) is a multicenter, phase 2, randomized, double-blind, placebo-controlled trial of 3 vaccine strategies in healthy children (ages 1–17) and adults, with projected 5 years of follow-up (NCT02876328). Using validated assays (GP-ELISA and PRNT), we measured antibody responses after 1-dose rVSVΔG-ZEBOV-GP, 2-dose rVSVΔG-ZEBOV-GP (given on Day 0 and Day 56), or placebo. Furthermore, we quantified vaccine virus shedding in a subset of children's saliva using RT-PCR.ResultsIn total, 819 children and 783 adults were randomized to receive rVSVΔG-ZEBOV-GP (1 or 2 doses) or placebo. A single dose of rVSVΔG-ZEBOV-GP increased antibody responses by Day 28 that were sustained through Month 12. A second dose of rVSVΔG-ZEBOV-GP given on Day 56 transiently boosted antibody concentrations. In vaccinated children, GP-ELISA titers were superior to placebo and non-inferior to vaccinated adults. Vaccine virus shedding was observed in 31.7% of children, peaking by Day 7, with no shedding observed after Day 28 post-dose 1 or any time post-dose 2.ConclusionsA single dose of rVSVΔG-ZEBOV-GP induced robust antibody responses in children that was non-inferior to the responses induced in vaccinated adults. Vaccine virus shedding in children was time-limited and only observed after the first dose. Overall, these data support the use of rVSVΔG-ZEBOV-GP for the prevention of EVD in at-risk children.Clinical Trials Registration. The study is registered at ClinicalTrials.gov (NCT02876328), the Pan African Clinical Trials Registry (PACTR201712002760250), and the European Clinical Trials Register (EudraCT number: 2017-001798-18).

100 Deals associated with rVSV Nipah vaccine(Public Health Vaccines)

R&D Status

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Henipavirus Infections	Phase 1	US	National Institute of Allergy & Infectious Diseases	02 Feb 2022

Clinical Result

Indication

Phase

Evaluation

View All Results

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

Chat with Hiro

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis


No Data

rVSV Nipah vaccine(Public Health Vaccines)

Overview

Basic Info

Related

R&D Status

Clinical Result

Translational Medicine

Deal

Core Patent

Clinical Trial

Approval

Regulation